“All IND-enabling activities and regulatory interactions remain on-track to initiate the Phase 1 clinical trial for SL-325 in the third quarter of this year. We believe SL-325 is fundamentally differentiated in its approach to targeting the clinically validated DR3/TL1A pathway and could potentially provide best-in-class clinical remission rates for IBD patients,” said Taylor Schreiber, CEO of Shattuck. “Spending last quarter continued to come in line with expectations, and wind-down activities associated with the discontinued oncology programs have now been substantially completed. We continue to be well-positioned to fund operations into 2027, beyond the results from our Phase 1 clinical trial for SL-325.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Strategic Pivot and Promising Trials: Shattuck Labs’ Growth Potential in IBD with SL-325
- Shattuck Labs’ SL-325: Promising Preclinical Results and Growth Potential Justify Buy Rating
- Shattuck Labs: Hold Rating Due to Early Pipeline Stages and Lack of Near-Term Catalysts
- Shattuck Labs reports Q4 EPS (37c), consensus (32c)
- Shattuck Labs’ SL-325: A Promising First-in-Class IBD Therapy with Significant Market Potential